A jury says Boston Scientific Corp. must pay $431 million in damages in a patent dispute over the medical device maker’s drug-coated stents.
The company said that federal jury in Marshall, Texas reached the damages award in a patent infringement lawsuit brought by Dr. Bruce Saffran. The jury found that Boston Scientific’s Taxus Express and Taxus Liberte stents infringe on a patent that Saffran holds.
Boston Scientific argues the verdict is unsupported by evidence and the law. The Natick, Massachusetts-based company plans to try to overturn the verdict in post-trial motions. If that’s unsuccessful, Boston Scientific says it will appeal.
Stents are tiny, mesh-wire tubes that prop open arteries after they have been surgically cleared of fatty plaque.
Topics Massachusetts
Was this article valuable?
Here are more articles you may enjoy.
New York Taxi Insurer Failed to Defend Uber in Crash Cases, Judge Says 
Meta Loses Insurance for Defense in Major Social Media Addiction Litigation 
US Offers $20 Billion Reinsurance Plan to Spur Gulf Oil Flow 
Travelers Stranded by War Learn Insurance Won’t Cover Flight Cancellations 
